Cross-agency comparison: 🇪🇺 EMA leads with 95 documents in 90 days

FDA vs EMA vs MHRA vs Health Canada — who's most active?

The EMA’s much higher document volume over the past 90 days may indicate the most active and continuously evolving regulatory environment among the four, with MHRA and Health Canada also showing steady output and the FDA comparatively quieter in aggregate. Sponsors should consider that Europe may require the most frequent horizon scanning and dossier maintenance, while UK and Canadian planning can likely be sequenced off a similarly active, but smaller, policy cadence. This could suggest that global filing strategy should prioritize stronger regulatory intelligence and flexible resource allocation for EU-facing programs, with cross-functional teams prepared to absorb more rapid guidance drift and submission-impacting updates in the European corridor.